Utility of glucagon-like-peptide-1-receptor agonists in mast cell activation syndrome.
Level 4 - case-series / case-control
Uncontrolled case series
PubMed 40675372 · doi:10.1016/j.amjms.2025.07.006
What was done
A case series evaluating the use of various glucagon-like peptide-1 receptor agonists (GLP-1RAs) in patients with refractory mast cell activation syndrome (MCAS).
What was found
Among 47 patients (mean age 39 years, range 15–71; 89% female), 89% showed clinical benefit across a broad range of symptoms associated with MCAS following treatment with GLP-1RAs. The abstract does not report specific drug names, dosages, treatment duration, or numerical symptom scores.
Why it matters
This study provides preliminary evidence that GLP-1 receptor agonists might alleviate symptoms in patients with treatment-refractory MCAS.
Limits
As an uncontrolled case series, the findings are subject to substantial risk of bias, placebo effects, and confounding. The sample was predominantly female (89%), and the abstract lacks objective outcome metrics, details on specific GLP-1RA agents, and safety or adverse event data.
Cited by
- supports GLP-1 receptors are present on immune cells, specifically on mast cells.